AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS:

1-24. (cancelled)

25. (currently amended) A controlled release composition, comprising:

a hydrophilic first matrix comprising a lipophilic phase and an amphiphilic phase,

wherein said lipophilic phase and said amphiphilic phase are in a second matrix together, and said second matrix is dispersed throughout the hydrophilic first matrix,

wherein said lipophilic phase comprises lipophilic compounds and an active ingredient at least partially incorporated in said lipophilic phase, [[and]]

wherein said amphiphilic phase comprises an active ingredient at least partially incorporated in said amphiphilic phase, and

wherein said controlled release composition is in a solid form.

26. (previously presented) The controlled release composition according to claim 25, wherein the lipophilic phase consists of lipophilic compounds with a melting point below 90°C.

27. (previously presented) The composition according to claim 25, further comprising compounds that are polar lipids of type I or II, ceramides, glycol alkyl ethers, esters of fatty acids with polyethylene glycols or diethylene glycols.

28. (previously presented) The composition according to claim 25, wherein the lipophilic phase comprises one or more compounds selected from the group consisting of unsaturated or hydrogenated alcohols or fatty acids, salts, esters or amides thereof, mono-, di- or triglycerides of fatty acids, the polyethoxylated derivatives thereof, waxes, and cholesterol derivatives.

29. (previously presented) The composition according to claim 25, wherein the hydrophilic matrix consists of hydrogel-forming compounds.

30. (previously presented) The composition according to claim 29, wherein the hydrophilic matrix consists of compounds selected from the group consisting of acrylic or methacrylic acid polymers or copolymers, alkylvinyl polymers,

hydroxyalkylcellulose, carboxyalkyl-cellulose, polysaccharides, dextrins, pectins, starches and derivatives, alginic acid, natural or synthetic gums, and polyalcohols.

31. (previously presented) The composition according to claim 25, further comprising a gastro-resistant coating.

32. (previously presented) The composition according to claim 31, wherein the gastro-resistant coating consists of methacrylic acid polymers or cellulose derivatives.

33. (previously presented) The composition according to claim 25, wherein said composition is in the form of tablets, capsules or minitablets.

34. (previously presented) The composition according to claim 26, wherein said composition is in the form of tablets, capsules or minitablets.

35. (previously presented) The composition according to claim 25, in which the active ingredient belongs to the therapeutical classes of analgesics, antitussives, bronchodilators, antipsychotics, selective β 2 antagonists, calcium antagonists, antiparkinson drugs, non-steroidal anti-inflammatory drugs, antihistamines, antidiarrheals and intestinal

antiinflammatories, spasmolytics, anxiolytics, oral antidiabetics, cathartics, antiepileptics, topical antimicrobials.

36. (previously presented) The composition according to claim 25, wherein the active ingredient is selected from the group consisting of mesalazine (5-aminosalicylic acid), budesonide, metformin, octylonium bromide, gabapentin, carbidopa, nimesulide, propionylilcarnitine, isosorbide mono- and dinitrate, naproxen, ibuprofen, ketoprofen, diclofenac, thiaprophenic acid, nimesulide, chlorhexidine, benzydamine, tibezonium iodide, cetylpyridinium chloride, benzalkonium chloride, and sodium fluoride.

37. (previously presented) The composition according to claim 25, further comprising bioadhesive substances.

38. (previously presented) A pharmaceutical composition, comprising the composition according to claim 25, in the form of tablets chewable or erodible in the buccal cavity or in the first portion of the gastrointestinal tract.

39. (previously presented) The method according to claim 25, wherein the amphiphilic matrix comprises 5 to 95% by weight of an active ingredient.